- Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions - https://eyedocnews.com -

Inotek Pharmaceuticals Presentations at ARVO 2009

Posted By Irv Arons On April 29, 2009 @ 5:48 pm In Glaucoma,Industry News,Meetings | Comments Disabled

Inotek Pharmaceuticals announced that preclinical data supporting the Company’s lead clinical-stage drug candidate in glaucoma, INO-8875, will be presented in a poster session at ARVO.

INO-8875 is a highly selective adenosine-1 receptor agonist currently completing a Phase 1/2 trial as a topical agent for the treatment of elevated intraocular pressure (IOP) associated with primary open angle glaucoma and ocular hypertension. The preclinical data suggests that INO-8875 lowers IOP primarily by restoring trabecular meshwork outflow, the most important outflow pathway to maintain IOP in healthy eyes. Additionally, INO-8875 may have a secondary mechanism of action to decrease IOP by reducing aqueous humor production.

Read [1] the full release.


Article printed from Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions: https://eyedocnews.com

URL to article: https://eyedocnews.com/001015-inotek-pharmaceuticals-presentations-at-arvo-2009/

URLs in this post:

[1] Read: http://www.inotekcorp.com/press_room/news_30.asp

Copyright © 2008 Eye Doc Talk. All rights reserved.